<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00017394</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02388</org_study_id>
    <secondary_id>01-013</secondary_id>
    <secondary_id>CDR0000068685</secondary_id>
    <nct_id>NCT00017394</nct_id>
  </id_info>
  <brief_title>Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast Cancer</brief_title>
  <official_title>A Phase II Study of Bevacizumab in Combination With Vinorelbine in Stage IV Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase II trial to study the effectiveness of bevacizumab combined with vinorelbine in&#xD;
      treating patients who have stage IV breast cancer. Monoclonal antibodies such as bevacizumab&#xD;
      can locate tumor cells and either kill them or deliver tumor-killing substances to them&#xD;
      without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor&#xD;
      cells from dividing so they stop growing or die. Combining monoclonal antibody with&#xD;
      chemotherapy may kill more cancer cells&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the complete and partial response rates in patients with stage IV breast cancer&#xD;
      treated with concurrent bevacizumab and vinorelbine.&#xD;
&#xD;
      II. Determine the side effects of this regimen in these patients. III. Determine the time to&#xD;
      disease progression in patients treated with this regimen.&#xD;
&#xD;
      IV. Determine the time on study (a reflection of time to progression, treatment-related side&#xD;
      effects, and patient preference) of patients treated with this regimen.&#xD;
&#xD;
      V. Assess urine protein/creatinine ratio and serum complement levels as screening measures&#xD;
      for renal injury in patients treated with bevacizumab.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive bevacizumab IV over 30-90 minutes once every other week and vinorelbine IV&#xD;
      over 6-10 minutes once weekly for 8 weeks. Treatment repeats every 8 weeks for 4 courses in&#xD;
      the absence of disease progression or unacceptable toxicity. Patients with complete or&#xD;
      partial response or stable disease after completion of the fourth course may receive&#xD;
      additional courses of concurrent bevacizumab and vinorelbine administered once every other&#xD;
      week or may continue therapy on the schedule as above.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 56 patients will be accrued for this study within 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2001</start_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate to combination therapy with bevacizumab and vinorelbine, defined by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria</measure>
    <time_frame>Up to 6 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>Time from the first treatment on study until the time of documented disease progression, assessed up to 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicities, graded according to the National Cancer Institute Common Toxicity Criteria (NCI CTC) v2.0</measure>
    <time_frame>Up to 6 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Male Breast Cancer</condition>
  <condition>Recurrent Breast Cancer</condition>
  <condition>Stage IV Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (bevacizumab, vinorelbine tartrate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive bevacizumab IV over 30-90 minutes once every other week and vinorelbine IV over 6-10 minutes once weekly for 8 weeks. Treatment repeats every 8 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with complete or partial response or stable disease after completion of the fourth course may receive additional courses of concurrent bevacizumab and vinorelbine administered once every other week or may continue therapy on the schedule as above.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (bevacizumab, vinorelbine tartrate)</arm_group_label>
    <other_name>anti-VEGF humanized monoclonal antibody</other_name>
    <other_name>anti-VEGF monoclonal antibody</other_name>
    <other_name>Avastin</other_name>
    <other_name>rhuMAb VEGF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinorelbine tartrate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (bevacizumab, vinorelbine tartrate)</arm_group_label>
    <other_name>Eunades</other_name>
    <other_name>navelbine ditartrate</other_name>
    <other_name>NVB</other_name>
    <other_name>VNB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (bevacizumab, vinorelbine tartrate)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed stage IV breast cancer&#xD;
&#xD;
               -  Patients without pathologic or cytologic confirmation of metastatic disease must&#xD;
                  have unequivocal evidence of metastasis by physical exam or radiologic study&#xD;
&#xD;
          -  Must meet 1 of the following criteria:&#xD;
&#xD;
               -  Received 1 or 2 prior conventional chemotherapy regimens for metastatic disease&#xD;
&#xD;
               -  Relapsed within 1 year after adjuvant chemotherapy and no prior chemotherapy for&#xD;
                  metastatic disease&#xD;
&#xD;
          -  At least 1 unidimensionally measurable lesion, meeting 1 of the following criteria:&#xD;
&#xD;
               -  At least 20 mm by conventional techniques&#xD;
&#xD;
               -  At least 10 mm by spiral CT scan&#xD;
&#xD;
          -  No CNS metastases by CT scan or MRI within the past 6 weeks&#xD;
&#xD;
          -  No prior or concurrent primary CNS tumor on physical exam&#xD;
&#xD;
          -  Disease progression after bone marrow or peripheral blood stem cell transplantation&#xD;
             allowed&#xD;
&#xD;
          -  HER2-positive tumors allowed if previously treated with trastuzumab (Herceptin)&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  Performance status - ECOG 0-2&#xD;
&#xD;
          -  Performance status - Karnofsky 60-100%&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 9 g/dL&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  No prior bleeding diathesis or coagulopathy&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST/ALT no greater than 2.5 times ULN&#xD;
&#xD;
          -  INR no greater than 1.5&#xD;
&#xD;
          -  Creatinine less than 2 mg/dL&#xD;
&#xD;
          -  Urine protein no greater than +1 by dipstick&#xD;
&#xD;
          -  Urine protein less than 500 mg by 24-hour urine collection&#xD;
&#xD;
          -  LVEF at least 50%&#xD;
&#xD;
          -  No prior stroke&#xD;
&#xD;
          -  No New York Heart Association class II-IV congestive heart failure&#xD;
&#xD;
          -  No serious cardiac arrhythmia requiring medication, including atrial fibrillation&#xD;
             requiring systemic anticoagulation&#xD;
&#xD;
          -  No grade II or greater peripheral vascular disease within the past year&#xD;
&#xD;
          -  No clinically significant peripheral artery disease&#xD;
&#xD;
          -  No deep vein thrombosis or embolism within the past 5 years&#xD;
&#xD;
          -  No arterial thromboembolic event within the past 6 months, including any of the&#xD;
             following:&#xD;
&#xD;
               -  Transient ischemic attack&#xD;
&#xD;
               -  Cerebrovascular accident&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  Myocardial infarction&#xD;
&#xD;
          -  No other significant cardiovascular disease&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No evidence of seizures not controlled with standard medical therapy&#xD;
&#xD;
          -  No prior allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to bevacizumab or other agents used in the study&#xD;
&#xD;
          -  Prior mild infusion reaction to trastuzumab allowed&#xD;
&#xD;
          -  No serious non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  No significant traumatic injury within the past 4 weeks&#xD;
&#xD;
          -  No other concurrent illness (such as active infection) that would require active&#xD;
             treatment or preclude study&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior bevacizumab&#xD;
&#xD;
          -  No other prior experimental angiogenesis inhibitors&#xD;
&#xD;
          -  At least 2 weeks since prior trastuzumab and recovered&#xD;
&#xD;
          -  Concurrent epoetin alfa or filgrastim (G-CSF) allowed&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 2 weeks since prior chemotherapy and recovered&#xD;
&#xD;
          -  No prior vinorelbine&#xD;
&#xD;
          -  No more than 2 prior conventional chemotherapy regimens for metastatic breast cancer&#xD;
&#xD;
          -  Prior hormonal therapy allowed&#xD;
&#xD;
          -  At least 1 week since prior radiotherapy and recovered&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior major surgical procedure or open biopsy&#xD;
&#xD;
          -  At least 1 week since prior fine-needle aspiration except in the breast&#xD;
&#xD;
          -  No concurrent major surgical procedure&#xD;
&#xD;
          -  Recovered from the toxic effects of any prior therapy&#xD;
&#xD;
          -  At least 10 days since prior oral or parenteral anticoagulants (e.g., heparin or&#xD;
             warfarin) except to maintain the patency of permanent, indwelling central venous&#xD;
             catheter&#xD;
&#xD;
          -  At least 10 days since prior thrombolytic agents&#xD;
&#xD;
          -  No chronic aspirin therapy greater than 325 mg per day or non-steroidal&#xD;
             anti-inflammatory medications that inhibit platelet function&#xD;
&#xD;
          -  No concurrent COX-2 inhibitors that inhibit platelet function&#xD;
&#xD;
          -  No other concurrent investigational or commercial agents or therapies for the&#xD;
             malignancy&#xD;
&#xD;
          -  No concurrent antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No concurrent ketoconazole, zidovudine, or macrolide antibiotics&#xD;
&#xD;
          -  No concurrent oral or parenteral anticoagulants except to maintain patency of&#xD;
             permanent, indwelling central venous catheter&#xD;
&#xD;
          -  No concurrent thrombolytic agent&#xD;
&#xD;
          -  Concurrent bisphosphonates allowed&#xD;
&#xD;
          -  Concurrent celecoxib or rofecoxib allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harold Burstein</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>June 6, 2001</study_first_submitted>
  <study_first_submitted_qc>June 11, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2003</study_first_posted>
  <last_update_submitted>January 16, 2013</last_update_submitted>
  <last_update_submitted_qc>January 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms, Male</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

